To Örebro University

oru.seÖrebro universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Dread and Risk Elimination Premium for the Value of a Statistical Life
The Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Clinical Sciences, Malmö, Health Economics Unit, Lund University, Lund, Sweden.
The Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Clinical Sciences, Malmö, Health Economics Unit, Lund University, Lund, Sweden; School of Economics and Management, Institute of Economic Research, Lund University, Lund, Sweden; Department of Economics, School of Economics and Management, Lund University, Lund, Sweden.
Örebro universitet, Handelshögskolan vid Örebro Universitet.ORCID-id: 0000-0003-1172-1076
The Swedish Institute for Health Economics (IHE), Lund, Sweden.
2019 (engelsk)Inngår i: Risk Analysis, ISSN 0272-4332, E-ISSN 1539-6924, Vol. 39, nr 11, s. 2391-2407Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The value of a statistical life (VSL) is a widely used measure for the value of mortality risk reduction. As VSL should reflect preferences and attitudes to risk, there are reasons to believe that it varies depending on the type of risk involved. It has been argued that cancer should be considered a "dread disease," which supports the use of a "cancer premium." The objective of this study is to investigate the existence of a cancer premium (for pancreatic cancer and multiple myeloma) in relation to road traffic accidents, sudden cardiac arrest, and amyotrophic lateral sclerosis (ALS). Data were collected from 500 individuals in the Swedish general population of 50-74-year olds using a web-based questionnaire. Preferences were elicited using the contingent valuation method, and a split-sample design was applied to test scale sensitivity. VSL differs significantly between contexts, being highest for ALS and lowest for road traffic accidents. A premium (92-113%) for cancer was found in relation to road traffic accidents. The premium was higher for cancer with a shorter time from diagnosis to death. A premium was also found for sudden cardiac arrest (73%) and ALS (118%) in relation to road traffic accidents. Eliminating risk was associated with a premium of around 20%. This study provides additional evidence that there exist a dread premium and risk elimination premium. These factors should be considered when searching for an appropriate value for economic evaluation and health technology assessment.

sted, utgiver, år, opplag, sider
Blackwell Publishing, 2019. Vol. 39, nr 11, s. 2391-2407
Emneord [en]
Cancer premium, VSL, risk elimination, stated preferences, willingness to pay
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-74704DOI: 10.1111/risa.13341ISI: 000494483400005PubMedID: 31194898Scopus ID: 2-s2.0-85067397721OAI: oai:DiVA.org:oru-74704DiVA, id: diva2:1325681
Merknad

Funding Agencies:

Johnson & Johnson USA

Janssen Biotech Inc

Tilgjengelig fra: 2019-06-17 Laget: 2019-06-17 Sist oppdatert: 2019-11-22bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Hultkrantz, Lars

Søk i DiVA

Av forfatter/redaktør
Hultkrantz, Lars
Av organisasjonen
I samme tidsskrift
Risk Analysis

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 252 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf